Safety of Early Removal of Chest Tubes After Thoracoscopic Lung Biopsies

Status Not yet recruiting

Clinical Trial Summary

prospective study, involves 60 patients underwent thoracoscopic surgery, the patients will be divided into two groups, the first group will undergo early chest tube removal - after three hours, the second group will have late chest tube removal according to the department's protocol.

the study aims to prove the possibility and non inferiority for early chest tube removal for thoracoscopic surgeries with non complicated surgical course.

Clinical Trial Description

Presence of chest tube post thoracoscopic surgery is associated with increased morbidities like wound infection, pain, and prolong the hospital admission Corse, in the other hand, early chest tube removal is associated with increased the need for recurrent active intervention like pleural tapping for re-accumulated pleural effusion.

Method: randomized prospective study includes 60 patients who underwent thoracoscopic lobectomy/segmentectomy/ thoracoscopic mediastinal biopsy.

The study will exclude patients with difficult operative course ( intraoperative finding of significant adhesions/ intraoperative injury of the lung parenchyma/ intraoperative bleeding/failure of extubation ) and patient with post operative findings of ( bleeding in the chest tube more than 100 ml in the first hour, persistent air leak, non expanded lung on chest x-ray ) The patients will be divided into two groups, the first group - 30 patients - will undergo chest tube removal after three hours, and the second group will undergo chest tube removal according to the treating department protocol.

All patients will be evaluated regarding the pain level - subjective and objective -, admission period, infection, and the need for invasive intervention.

The patients will be evaluated during the admission, after one week and after two weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02727218
Study type	Interventional
Source	Rambam Health Care Campus
Contact	Ran Kremer, MD
Phone	00972502063189
Email	r_kremer@rambam.health.gov.il
Status	Not yet recruiting
Phase	N/A
Start date	May 2016
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Completed	`NCT04908397` - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	Phase 1
Terminated	`NCT03309358` - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis	Phase 1
Completed	`NCT03682354` - ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery	N/A
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Completed	`NCT03626519` - Effects of Menthol on Dyspnoea in COPD Patients	N/A
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Completed	`NCT04874948` - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment	Phase 1
Completed	`NCT02926768` - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors	Phase 1
Completed	`NCT01443845` - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)	Phase 4
Completed	`NCT00269256` - Stress, Environment, and Genetics in Urban Children With Asthma	N/A
Terminated	`NCT00233207` - IC14 Antibodies to Treat Individuals With Acute Lung Injury	Phase 2
Completed	`NCT00281216` - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations	N/A
Recruiting	`NCT00129350` - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation	Phase 1
Active, not recruiting	`NCT00115297` - Montelukast for Early Life Wheezing	Phase 2/Phase 3
Completed	`NCT00091767` - Genetic Studies in Difficult to Treat Asthma: TENOR	N/A
Completed	`NCT00094276` - Intervention for Improving Asthma Care for Minority Children in Head Start	N/A
Completed	`NCT00233168` - Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents	N/A
Completed	`NCT00069823` - Study of Acid Reflux in Asthma	Phase 3
Completed	`NCT00089752` - Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.